For this generation
More recently, September 2006 saw the introduction of the first pneumococcal conjugate vaccine (manufactured by Wyeth) into the UK childhood immunisation schedule, which was heralded by patient groups including the Meningitis Research Foundation and the Meningitis Trust as a major step forward in child health in the UK. The World Health Organization (WHO) now recommends the priority inclusion of Wyeth's pneumococcal conjugate vaccine in national childhood immunisation programmes worldwide.1
Wyeth has recently reached an agreement with GAVI (the Global Alliance for Vaccines and Immunisation) to provide a donation of more than three million doses of the vaccine to immunise African children in GAVI-eligible countries. The vaccine programme begins this year in Rwanda and Gambia.
In the UK, Wyeth Vaccines has been working in partnership with the NHS and healthcare professionals to support successful flu vaccinations for over ten years, building a dedicated vaccines service around the real and practical needs of GP Practices. Healthcare professionals have told Wyeth that the reliability and accuracy of flu vaccine delivery is an important factor in the supply of flu vaccine. Wyeth are proud of the fact that over 70% of our current customers have been ordering flu vaccines from us for three or more years.2 Wyeth Vaccines has also developed an extensive range of materials and resources on their new improved website to support flu vaccination campaign delivery in order to help make GP surgeries as successful as possible in meeting practice targets.
So what's new? Well, there are some really helpful developments to the website; the introduction of an SMS service for your patients to help remind them when they are due for a vaccination, a link to order surgery support materials and downloadable letters and presentations. There is even an online calculator that works out the financial returns you can expect with your flu vaccine.
For all our futures
The company is currently in the search for both active and passive immunotherapies for Alzheimer's disease. Teamed with scientists from Wyeth's small molecule and biopharmaceuticals programmes, Wyeth hopes to be able to bring forward successful treatments to combat Alzheimer's disease.
Wyeth are leading specialists in vaccines, with a reputation for innovation and quality; twice winners of the Prix Galien awards, for Meningitec® (its conjugate vaccine against Meningitis C) in 2002 and for Prevenar® (its pneumococcal conjugate vaccine) in 2004, Wyeth was also awarded the US Medal of Technology in 2007 for its pneumococcal conjugate vaccine - America's highest honour for technological achievement.
The website shows that Wyeth Vaccines continue to improve and develop their service for both patients and healthcare professionals; click on the link now www.wyethvaccines.co.uk to see how the new website can add an extra dimension to the resources behind your vaccination campaigns in 2009.
Wyeth Vaccines aim to lead the way to a healthier world. The investment in research is matched by a commitment to supporting the NHS in delivering immunisation programmes which protect all generations, both now and in the future.
References
1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization, March 2007- WHO position paper. Wkly Epidemiol Record 2007;12:93-104
2. Wyeth Data on File Flu Vaccines Customer Loyalty 2008 season
